Poly Medicure share price today

Poly Medicure Ltd's share price was ₹1,586.80 at the close on 4 November 2026. It has been falling for 1 week. That is 4.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,230 and ₹1,943, and at that close it sat 50% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Poly Medicure Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

Over the last 11 years the share price moved +978% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: foreign funds (FIIs) cut their stake for 7 quarters in a row and revenue up on a year earlier for 11 quarters in a row (every quarter we can compare).

1. Foreign funds (FIIs) cut their stake for 7 quarters in a row

   From 12.3% to 5.4% of the company by the September 2026 quarter.

2. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹525 crore, +30.3% on a year earlier.

   Why: Revenue rose because Europe recovered as new customers came back.

   From the earnings call on 10 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Poly Medicure reported revenue of ₹525 crore, up 30.3% from ₹403 crore a year earlier, and a profit of ₹85.0 crore, down 8.6% from ₹93.0 crore.

Poly Medicure results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Poly Medicure's management discussed these results on a call held on 10 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Poly Medicure closed at ₹1,586.80 on 4 November 2026, down 16.2% from ₹1,893.80 a year earlier (7 November 2025) and up 74.0% over five years. Its highest weekly close since March 2016 was ₹3,128.90 on 1 November 2024.

Poly Medicure share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Poly Medicure closed at ₹1,586.80, up 9.5% on the week and down 3.1% on the month. 28 Aug 2026: ex-date for a dividend of ₹3.50 a share, record date 29 Aug 2026.

Earlier

• 10 Aug 2026: Poly Medicure held its results call for April to June 2026. Management guided: FY27 consolidated revenue ₹2,300-2,400 crore, including full-year Pendra Care and Citieffe consolidation.
• Results for April to June 2026: Revenue up 30.3% and profit down 8.6% on a year earlier.

Poly Medicure paid ₹3.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.22% at the ₹1,586.80 close on 4 November 2026. The last was a dividend of ₹3.50 a share, ex-date 28 August 2026.

Poly Medicure dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Poly Medicure Ltd paid out 11% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 10 August 2026, Poly Medicure's management guided: FY27 consolidated revenue ₹2,300-2,400 crore, including full-year Pendra Care and Citieffe consolidation.

“We have enough on our plate right now with the existing businesses, and I do not think we will be ready to launch anything substantially new in the next few years.”Himanshu Baid, on the call for April to June 2026

What management guided

• FY27 standalone revenue ₹1,900-2,000 crore; domestic growth above 20% and international growth above 15%.
• FY27 operating margin: standalone 25-27%, expected toward the upper end, and consolidated 23-25%.
• Steady-state gross margin 68-69% standalone and 71-72% consolidated.
• FY27 capital spending ₹200-225 crore; Faridabad-Palwal planned by March 2027 and Noida commercially in April to June 2027.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 10 August 2026.

When Poly Medicure reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 revenue acceleration after the initial price-hike disruption - check standalone and organic consolidated growth against the maintained annual framework.

Poly Medicure is on one of our India lists: Small & mid cap stocks.

Poly Medicure Ltd earned ₹85.0 Cr of net profit in the Jun 2026 quarter, −8.6% on the same quarter a year earlier. Full-year FY26 profit was ₹321 Cr. Over 10 years profit has grown 20.9% a year on average. That is 16.2% of the quarter's revenue. The same quarter a year earlier earned ₹93.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹321 Cr (−5.3% on the year before).

Why profit moved: revenue changed +30.3% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −12.2% and revenue +18.4%. Profit is growing slower than sales: rising costs are taking part of the growth.

Poly Medicure Ltd reported ₹525 Cr of revenue in the Jun 2026 quarter, +30.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 16.4% a year on average. The last full year, FY26, came in at ₹1,875 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,998 Cr.

FY26 revenue was ₹1,875 Cr, +12.3% on the year before.

Recent pace: the last four quarters grew +18.4% on average, against 16.4% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +18.4%, against +17.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −12.3%, against +7.9% a year (rolling over).

Poly Medicure Ltd's operating margin was 24.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 21.0% and 28.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −2.4 percentage points on the year while gross margin changed +5.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 81% of Poly Medicure Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹246 Cr of operating cash against ₹321 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹724 Cr of spending on assets, free cash was −₹478 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 81% of profit came in as cash: the cash cycle got 156 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 5.1× depreciation over three years. The next section checks what that spending is building.

Poly Medicure Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 335 days in FY26, up from 179 days in FY21. It spent ₹1,342 Cr on assets over the last 3 years. Customers take 103 days to pay, and stock sits for 323 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,875 Cr, each day of that cycle ties up about ₹5.1 Cr, so roughly ₹1,721 Cr is tied up in the business at any time.

FY26: customers took 103 days to pay and stock sat for 323 days, about 10.6 months of sales sitting as stock, for a full cycle of 335 days, longer than FY21's 179.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 323 days. Customers pay about 103 days after that. Suppliers are paid at 91 days. Together that makes the 335-day cycle.

Spending on assets: ₹1,342 Cr over the last 3 years, against ₹262 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹99.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Poly Medicure Ltd's P/E is 50.2×, in the middle of its own history: higher than 53% of past readings. Its usual P/E (the middle reading) is 47.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹31.09.